There would be an increase in fees upto 1.7 % from April 1st 2018 as mentioned in the notification of Commission Regulation (EU) No 2018/471 (amending Council Regulation (EC) No 297/95), the fees however would be implemented for all activities carried out by the agency except pharmacovigilance.
Apart from Pharmacovigilance the agency has also exempted fees of Micro Small or Medium Sized Enterprise, Orphan Medicinal Products, Medicinal Products for Paediatric Use, Advanced Therapy Medicinal Products etc… Detailed information on has been provided on an explanatory note.
The agency every year revises its fees as per the statistical data from EUROSTAT (European Union’s statistical office), the current revision is made in accordance with the inflation rate for 2017.
1. Explanatory note on general fees payable to the European Medicines Agency
2. COMMISSION REGULATION (EU) 2018/471 of 21 March 2018
Brought to you by:
Think-i (www.thinki.in) , Quality driven Solution providers in Clinical research and Pharmacovigilance
We at Think I are committed to provide cost effective & robust pharmacovigilance solutions.
Think I partners with AB Cube, France to provide SafetyEasy PV™ pharmacovigilance database which is fully evolutive and pre-validated, hosted through cloud based technology and delivered through software as a solution (SaaS) in a web based access.